心脏骤停后综合征中使用CytoSorb®进行细胞因子血液吸附:一项先导性随机对照试验
这项先导性随机对照试验纳入21例心脏骤停后入住ICU、有心脏骤停后综合征风险的患者(需去甲肾上腺素>0.2 µg/kg/min,和/或乳酸>6 mmol/l,和/或ROSC时间>25 min),随机分为标准治疗组(SOC)或SOC加血液吸附(HA)组。HA在入ICU后18(11,23)小时内启动,中位持续21(14,24)小时,除aPTT升高趋势(5例(50%)vs 2例(18%),p=0.18)和轻度血小板减少趋势外耐受良好。48小时IL-6中位相对下降HA组为75%(60,94),SOC组为5%(-47,70),p=0.06,未达统计学显著。作者认为未来试验需要进一步明确HA在心脏骤停后的作用,并应纳入细胞因子评估以富集研究人群。
要点
- 纳入标准:心脏骤停后入住ICU、可能发生PCAS,需去甲肾上腺素>0.2 µg/kg/min,和/或乳酸>6 mmol/l,和/或ROSC时间>25 min;需ECMO或肾脏替代治疗者排除。
- HA在入ICU后18(11,23)小时启动,中位持续21(14,24)小时,使用CytoSorb®和局部肝素-鱼精蛋白抗凝,作为独立治疗进行24小时。
- 48小时IL-6中位相对下降:HA组75%(60,94)vs SOC组5%(-47,70),p=0.06,未达统计学显著。
- aPTT升高发生率HA组5例(50%)vs SOC组2例(18%),p=0.18;第1天轻度(100-150 G/L)血小板减少HA组5例(50%)vs SOC组2例(18%),p=0.18。
- 随机化时IL-6血浆水平<100 pg/mL者10例(48%),>1000 pg/mL者6例(29%)。
适用人群与场景
- 心脏骤停后入住ICU、可能发生心脏骤停后综合征(PCAS)的患者:需去甲肾上腺素>0.2 µg/kg/min,和/或血清乳酸>6 mmol/l,和/或ROSC时间>25 min。
- 排除需ECMO或肾脏替代治疗的患者。
- 共纳入21例,其中16例(76%)为院外心脏骤停。
诊断标准与关键阈值
- PCAS风险纳入条件:需去甲肾上腺素>0.2 µg/kg/min,和/或血清乳酸>6 mmol/l,和/或ROSC时间>25 min。
- 排除标准:需ECMO或肾脏替代治疗。
处置流程与药物剂量
- 随机分为标准治疗(SOC)或SOC加血液吸附(HA)。
- HA使用CytoSorb®和局部肝素-鱼精蛋白抗凝,作为独立治疗进行24小时。
- HA在入ICU后18(11,23)小时内启动,中位持续时间21(14,24)小时。
- 随机化后72小时内收集系列血浆细胞因子水平。
研究设计与关键结果
- 先导性随机对照试验,纳入21例心脏骤停后入住ICU、有PCAS风险的患者,HA组10例,SOC组11例。
- 中位(IQR)ROSC时间30(20,45)分钟;16例(76%)为院外心脏骤停。
- HA在所有分配至HA组的患者中于入ICU后18(11,23)小时内启动,中位持续时间21(14,24)小时。
- 干预耐受良好,除aPTT升高趋势(5例(50%)vs 2例(18%),p=0.18)和第1天轻度(100-150 G/L)血小板减少(5例(50%)vs 2例(18%),p=0.18)。
- 随机化时IL-6血浆水平<100 pg/mL者10例(48%),>1000 pg/mL者6例(29%)。
- 48小时IL-6中位相对下降:HA组75%(60,94)vs SOC组5%(-47,70),p=0.06。
证据类型、等级与局限
- 证据类型:先导性随机对照试验。
- 试验注册:NCT03523039,注册日期2018年5月14日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在心脏骤停后综合征高危患者中,HA可行、安全,并与细胞因子血浆水平非显著下降相关。
- 作者认为,未来试验需要进一步明确HA在心脏骤停后的作用,并应纳入细胞因子评估以富集研究人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hemoadsorption (HA) might mitigate the systemic inflammatory response associated with post-cardiac arrest syndrome (PCAS) and improve outcomes. Here, we investigated the feasibility, safety and efficacy of HA with CytoSorb® in cardiac arrest (CA) survivors at risk of PCAS.
METHODS: In this pilot randomized controlled trial, we included patients admitted to our intensive care unit following CA and likely to develop PCAS: required norepinephrine (> 0.2 µg/kg/min), and/or had serum lactate > 6 mmol/l and/or a time-to-return of spontaneous circulation (ROSC) > 25 min. Those requiring ECMO or renal replacement therapy were excluded. Eligible patients were randomly allocated to either receive standard of care (SOC) or SOC plus HA. Hemoadsorption was performed as stand-alone therapy for 24 h, using CytoSorb® and regional heparin-protamine anticoagulation. We collected feasibility, safety and clinical data as well as serial plasma cytokines levels within 72 h of randomization.
RESULTS: We enrolled 21 patients, of whom 16 (76%) had out-of-hospital CA. Median (IQR) time-to-ROSC was 30 (20, 45) minutes. Ten were assigned to the HA group and 11 to the SOC group. Hemoadsorption was initiated in all patients allocated to the HA group within 18 (11, 23) h of ICU admission and conducted for a median duration of 21 (14, 24) h. The intervention was well tolerated except for a trend for a higher rate of aPTT elevation (5 (50%) vs 2 (18%) p = 0.18) and mild (100-150 G/L) thrombocytopenia at day 1 (5 (50%) vs 2 (18%) p = 0.18). Interleukin (IL)-6 plasma levels at randomization were low (< 100 pg/mL) in 10 (48%) patients and elevated (> 1000 pg/mL) in 6 (29%). The median relative reduction in IL-6 at 48 h was 75% (60, 94) in the HA group versus 5% (- 47, 70) in the SOC group (p = 0.06).
CONCLUSIONS: In CA survivors at risk of PCAS, HA was feasible, safe and was associated with a nonsignificant reduction in cytokine plasma levels. Future trials are needed to further define the role of HA after CA. Those studies should include cytokine assessment to enrich the study population.
TRIAL REGISTRATION: NCT03523039, registered 14 May 2018.
参考来源
- Monard C, Bianchi N, Poli E, et al. Cytokine hemoadsorption with CytoSorb® in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care. 2023. PMID: 36691082. doi:10.1186/s13054-023-04323-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。